TRACON Pharmaceuticals, Inc. (TCON)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.3900 |
| Open | 1.5800 |
| Bid | 1.6400 x 2200 |
| Ask | 1.6800 x 900 |
| Day's Range | 1.5100 - 1.7900 |
| 52 Week Range | 1.2430 - 7.2290 |
| Volume | |
| Avg. Volume | 91,729 |
| Market Cap | 32.475M |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5950 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.38 |
- GlobeNewswire
TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with life science companies through a profit-share, revenue share, or franchise model, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will participate in a
- GlobeNewswire
TRACON Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with life science companies through a profit-share, revenue share, or franchise model, today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporat
- GlobeNewswire
TRACON Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with companies to develop and commercialize innovative products in the U.S., today announced financial results for the first quarter ended March 31, 2022. The Company will host a conference call
